Trial Profile
QT-Cab: An Open-Label Study to Investigate the Effect of Cabazitaxel on the QTc Interval in Cancer Patients.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 Nov 2015
Price :
$35
*
At a glance
- Drugs Cabazitaxel (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Acronyms QT-Cab
- Sponsors Sanofi
- 15 Dec 2011 Additional locations identified as reported by ClinicalTrials.gov.
- 15 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 08 Nov 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.